Active || Exited
3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. The company is manufacturing two leading products: EPIAO, a recombinant erythropoietin (rhEPO) injection for anemia in kidney disease and dialysis and anemia associated with chemotherapy and TPIAO, a recombinant human thrombopoietin (rhTPO) injection for chemotherapy induced thrombocytopenia.
AADi is a clinical stage biopharmaceutical company led by Dr. Neil Desai, an inventor of Abraxane®, ABI-009 and the nab® technology platform. Aadi’s lead product is ABI-009, a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin.
Accuragen AccuraGen is a molecular diagnostics and research service-provider company focusing on the development and commercialization of innovative and noninvasive liquid biopsy assays for cancer mutation detection using circulating DNA. This company has developed proprietary ultra-accurate, sensitive, flexible, and scalable technologies to accommodate diversified clinical and research needs.
Apexigen Apexigen is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company’s pipeline of immuno-oncology therapeutic candidates is led by the APX005M program, which is currently in clinical development.
Arcus Biosciences Arcus Biosciences is a biotechnology company focused on the discovery and development of innovative cancer immunotherapies. Arcus was founded in 2015 by Terry Rosen and Juan Jaen, the co-founders of Flexus Biosciences, which in February 2015 was acquired by Bristol-Myers Squibb to access Flexus’s IDO inhibitor, which was in preclinical development at the time and is now referred to as BMS-986205.
Ariagen is a new company founded by Decheng Capital focused on an innovative approach to treating cancer using novel modulators of the immune system.
ARMO Biosciences ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors.
BCFoods is a global leading food/vegetable ingredient supplier with a full supply chain control and strategically aligned global distribution platform. The company is the preferred partner for large multinational consumer food companies, and has recently initiated e-commerce and in-store business for its domestic and imported products.
CardiMED is a medical device company addressing the large and growing market for advanced cardiovascular devices in China.
Epimab Biotherapeutics EpimAb Biotherapeutics is a biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.


GenapSys is a life sciences / diagnostics company developing a disruptive DNA-sequencing technology that enables fast, accurate, and ultra-low cost genetic testing and research.


GRAIL is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection.
GYT Healthcare Services is a leading domestic hemodialysis service provider in China. GYT operates its hemodialysis services in a non-capital intensive model by partnering with existing hemodialysis centers at Tier 2 hospitals, community hospitals/clinics, or hospitals who have yet to offer hemodialysis service, to provide value-added services.
Hummingbird Bioscience Hummingbird Bioscience is a highly innovative biotech company, with facilities in Singapore and Silicon Valley, focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics
Insight Lifetech is a medical device company dedicated to developing world class interventional diagnostic cardiology devices
Invitae Invitae is a genetic information company with a mission to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today.
Ketai Medical

Ketai Medical is a medical device company focusing on registration and commercialization of innovative and FDA-approved prosthetic hip and knee joint implants for the China market.

Levitas LevitasBio is an early stage life science tools company developing a single-cell imaging and profiling platform based on magnetic levitation technology called the levitation image cytometry platform invented at Stanford and Harvard universities.
ReadCoor is is leading the next generation of “omics” by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients.


SentreHeart is a commercial stage medical device company with a novel suture delivery and tissue closure device for multiple clinical applications.
Shenzhen GeneMDx Biotech. Co., Ltd

Shenzhen GeneMDx Biotech. Co., Ltd is a premier Chinese distributor of medical equipment/diagnostic products and trusted partners for multinational companies. The company is also developing diagnostic assays tailored to the China market for detection of various targets including infectious disease.

SINO Medical Sciences Technology

SINO Medical Sciences Technology is a medical device company dedicated to developing, manufacturing and commercializing products for percutaneous coronary intervention for the Chinese market. BuMA, the company's lead product, is a SFDA approved drug (sirolimis, Rapamycin®) eluting, stainless steel stent.

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.